EP0100752A2 - Procédé de préparation d'un vaccin contre la rage, support et moyen pour l'administrer et procédé d'immunisation orale - Google Patents
Procédé de préparation d'un vaccin contre la rage, support et moyen pour l'administrer et procédé d'immunisation orale Download PDFInfo
- Publication number
- EP0100752A2 EP0100752A2 EP83810344A EP83810344A EP0100752A2 EP 0100752 A2 EP0100752 A2 EP 0100752A2 EP 83810344 A EP83810344 A EP 83810344A EP 83810344 A EP83810344 A EP 83810344A EP 0100752 A2 EP0100752 A2 EP 0100752A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- vaccine
- foxes
- bhk
- sad
- rabies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002649 immunization Methods 0.000 title claims description 8
- 238000000034 method Methods 0.000 title claims 6
- 229960003127 rabies vaccine Drugs 0.000 title 1
- 241000700605 Viruses Species 0.000 claims abstract description 16
- 241000282421 Canidae Species 0.000 claims abstract description 9
- 241000711798 Rabies lyssavirus Species 0.000 claims abstract description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 5
- 210000003292 kidney cell Anatomy 0.000 claims abstract description 4
- 241000699800 Cricetinae Species 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 18
- 229960005486 vaccine Drugs 0.000 claims description 15
- 206010037742 Rabies Diseases 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 8
- 102000002322 Egg Proteins Human genes 0.000 claims description 6
- 108010000912 Egg Proteins Proteins 0.000 claims description 6
- 235000013345 egg yolk Nutrition 0.000 claims description 6
- 210000002969 egg yolk Anatomy 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 244000309466 calf Species 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims description 2
- 239000012894 fetal calf serum Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000011888 foil Substances 0.000 claims 2
- 239000000463 material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920003023 plastic Polymers 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20061—Methods of inactivation or attenuation
- C12N2760/20064—Methods of inactivation or attenuation by serial passage
Definitions
- the aim of the invention is to find a means which is suitable for preventing the spread of rabies by artificial immunization of the fox population and for reducing or eliminating contaminated zones.
- an agent suitable for oral immunization which is characterized by an optionally stabilized vaccine according to the invention which is located in a container according to the invention.
- This agent is fixed in a bait suitable as a vehicle and laid out to eat in the contaminated area.
- the bait is eaten, the container is bitten and chewed, thereby releasing the vaccine in the mouth so that it can be absorbed through the oropharyngeal mucosa.
- this immunization leads to lifelong resistance to rabies viruses in foxes.
- the attenuated new rabies virus strain SAD is used as vaccine virus and is used on BHK 21 .
- the novel vaccine according to the invention is produced by storing cells of the virus strain SAD in a buffered medium at a temperature of 33 to 37 ° C., preferably 33 ° C., and a pH of 6.8 to 7.4, preferably 7.4 , preferably by adding a bicarbonate solution, and inoculated with a cell density of 0.5 to 4 ⁇ 10 5 , preferably 2 ⁇ 10 5 cells per ml of medium, preferably in Roux bottles.
- virus After the formation of a complete cell lawn, it is detached, preferably with trypsin-verse solution, and if necessary diluted in accordance with the increased cell count and sown again.
- the virus is harvested from the cell supernatant after approximately 48 to 72 hours, preferably 48 hours. In compliance with these conditions, virus titres of 10 7.0 to 10 7.5 I are regularly obtained. E ./ml received.
- a cell transfer is dispensed with, a higher virus dose can and must be inoculated initially in order to obtain appropriate virus titers.
- the vaccine is exposed to the environment over the 12 to 72 hour period from when the bait is cast to when it is picked up by the fox. Heat, bait or packaging material can drastically reduce the infectivity of the attenuated virus and thereby cancel out its immunizing effect. Therefore, the vaccine is preferably stabilized so that even at elevated temperatures, e.g. 37 ° C, within e.g. No virus titer loss greater than 90% occurs for 72 hours. Conversely, it is expedient if the living virus used is inactivated spontaneously after a certain time.
- the bowl film can, for example, consist of a rigid PVC film made of plasticizer-free hard PVC, preferably 250 p thick, VC content ⁇ 1 ppm and a cover sheet aluminum film, preferably 40 ⁇ thick, which is thermo-lacquered on the inside (vinyl base 5 to 6 g / m 2 ).
- the agent according to the invention consists of a container according to the invention filled with ml, preferably 1.8 to 2 ml, of vaccine optionally stabilized with egg yolk.
- the minimum dose for the field application is preferably 10 7 tissue culture infectious units.
- the agent is now fixed in a bait suitable as a vehicle so that the vaccine is released in the mouth when the bait is eaten and is absorbed through the oropharyngeal mucosa.
- bait e.g. Chicken heads or minced meat can be used.
- An SAD strain of rabies virus adapted to dog kidney cells is used. This is going to the baby Hamster kidney cell line BHK 21 is adapted by incubating it in Roux bottles in BHK growth medium with the addition of 5% calf serum and 3% fetal calf serum at 33 ° C and a pH between 6.8 to 7.4 and at intervals of 2 to 3 days passaged.
- the cells are inoculated in suspension at a cell density of 0.5 to 2 ⁇ 10 5 cells per ml of medium. After approximately 48 hours, the cell lawn is completely closed and is detached with a trypsin solution of verse and diluted approximately three times in accordance with the increased number of cells and sown again. After a further 48 to 72 hours, the virus is harvested from the cell supernatant. Further results of these tests are summarized in Table 1.
- Virus titration is carried out on cover glass cultures of BHK 21 cells in the Multiwell dish from Costar.
- the Costar plate has 24 depressions with a flat bottom, a diameter of 16 mm and a depth of 18 mm.
- the virus suspended in the BHK medium is mixed with 10% egg yolk as a stabilizer and 2 ml of the product in a push-through pack with a dish film made of a 250 p thick, rigid PVC film made of unplasticized rigid PVC with a VC content of ⁇ 1 ppm, and a cover sheet film made of 40 .mu.m thick, thermally lacquered (vinyl base 5 to 6 g / m 2 ) aluminum film filled and sealed airtight.
- This vaccine virus amount of approx. 10 7 IU per 2 ml, intended for field trials, is fixed in chicken heads and designed as bait in this form.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH4699/82 | 1982-08-04 | ||
| CH469982 | 1982-08-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0100752A2 true EP0100752A2 (fr) | 1984-02-15 |
| EP0100752A3 EP0100752A3 (fr) | 1985-04-17 |
Family
ID=4280970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP83810344A Withdrawn EP0100752A3 (fr) | 1982-08-04 | 1983-08-02 | Procédé de préparation d'un vaccin contre la rage, support et moyen pour l'administrer et procédé d'immunisation orale |
Country Status (1)
| Country | Link |
|---|---|
| EP (1) | EP0100752A3 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650673A (en) * | 1985-09-06 | 1987-03-17 | Connaught Laboratories Limited | Oral immunization of mammals |
| EP0210552A3 (en) * | 1985-07-26 | 1989-03-22 | Behringwerke Aktiengesellschaft | Live rabies vaccine |
| DE4420438A1 (de) * | 1994-06-10 | 1995-12-14 | Altrogge Holding S A | Tierköder |
| EA015458B1 (ru) * | 2010-11-03 | 2011-08-30 | Открытое Акционерное Общество "Институт Биотехнологий Ветеринарной Медицины" | Вакцина против бешенства для оральной иммунизации диких плотоядных животных и способ её получения |
| WO2014168510A1 (fr) * | 2013-04-11 | 2014-10-16 | Федеральное Казенное Предприятие "Щелковский Биокомбинат" | Procédé de fabrication d'un vaccin antirabique |
| RU227338U1 (ru) * | 2024-04-03 | 2024-07-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Смоленская государственная сельскохозяйственная академия" | Капсула для приманки для оральной иммунизации диких плотоядных животных против бешенства |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2169581C1 (ru) * | 1999-11-23 | 2001-06-27 | Виноходов Владимир Олегович | Вакцинный препарат и способ вакцинации птиц |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3769415A (en) * | 1969-06-04 | 1973-10-30 | Connaught Labor Ltd | Method of preparing a killed vaccine for oral use |
| US4014991A (en) * | 1976-01-23 | 1977-03-29 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Oral rabies immunization of carnivores |
| GB1596653A (en) * | 1977-01-26 | 1981-08-26 | Gist Brocades Nv | Vaccine |
-
1983
- 1983-08-02 EP EP83810344A patent/EP0100752A3/fr not_active Withdrawn
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0210552A3 (en) * | 1985-07-26 | 1989-03-22 | Behringwerke Aktiengesellschaft | Live rabies vaccine |
| US4650673A (en) * | 1985-09-06 | 1987-03-17 | Connaught Laboratories Limited | Oral immunization of mammals |
| DE4420438A1 (de) * | 1994-06-10 | 1995-12-14 | Altrogge Holding S A | Tierköder |
| DE4420438C2 (de) * | 1994-06-10 | 1999-12-02 | Altrogge Holding S A | Tierköder |
| EA015458B1 (ru) * | 2010-11-03 | 2011-08-30 | Открытое Акционерное Общество "Институт Биотехнологий Ветеринарной Медицины" | Вакцина против бешенства для оральной иммунизации диких плотоядных животных и способ её получения |
| RU2440139C1 (ru) * | 2010-11-03 | 2012-01-20 | Открытое Акционерное Общество "Институт Биотехнологий Ветеринарной Медицины" | Вакцина против бешенства для оральной иммунизации диких плотоядных животных и способ ее получения |
| WO2014168510A1 (fr) * | 2013-04-11 | 2014-10-16 | Федеральное Казенное Предприятие "Щелковский Биокомбинат" | Procédé de fabrication d'un vaccin antirabique |
| RU2538617C2 (ru) * | 2013-04-11 | 2015-01-10 | Федеральное Казенное Предприятие "Щелковский Биокомбинат" | Способ получения антирабической вакцины |
| RU227338U1 (ru) * | 2024-04-03 | 2024-07-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Смоленская государственная сельскохозяйственная академия" | Капсула для приманки для оральной иммунизации диких плотоядных животных против бешенства |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0100752A3 (fr) | 1985-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schat et al. | Characterisation of two highly oncogenic strains of Marek's disease virus | |
| US4251509A (en) | Dry particulate vaccine for oral administration | |
| PL133923B1 (en) | Method of obtaining freeze dried hepatitis vaccine for ducks | |
| CH617588A5 (fr) | ||
| DE2817891A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| CH504532A (de) | Verfahren zur Züchtung pathogener Viren, Zellstamm zur Ausführung des Verfahrens und Anwendung des Verfahrens | |
| EP0100752A2 (fr) | Procédé de préparation d'un vaccin contre la rage, support et moyen pour l'administrer et procédé d'immunisation orale | |
| CH658192A5 (de) | Tollwut-impfstoff und verfahren zu seiner herstellung. | |
| CH639281A5 (de) | Verfahren zur herstellung eines praeparates zur behandlung von herpes-infektionen. | |
| DE2717919A1 (de) | Verfahren zur herstellung eines pferde-rhinopneumonievakzins und durch dieses verfahren hergestelltes vakzin | |
| DE69103130T2 (de) | Zellfreies Marekskrankheitvirus-Vakzin. | |
| JP3945842B2 (ja) | 弱毒性ニューカッスル病ウイルスワクチン | |
| DE69615656T2 (de) | Aviären infektiösen anämie mastgeflügel impfstoff | |
| KR20000069501A (ko) | 뉴우캐슬병에 대한 난내 백신화 | |
| US4650673A (en) | Oral immunization of mammals | |
| CA1136043A (fr) | Vaccins contre les maladies causees par les reovirus et procede de preparation | |
| DE69835346T2 (de) | Vakzine gegen infektiöse bursitis | |
| DE69737198T2 (de) | Sich gegenseitig schützende herpesviruszusammensetzung und verfahren zur deren herstellung und verwendung | |
| DE2328579A1 (de) | Varicella-vaccine | |
| EP0025116A1 (fr) | Procédé pour tester l'inactivation de vaccins et l'innocuité de produits sanguins ainsi que l'activité de produits chimiothérapeutiques ou de produits de désinfection contre l'hépatite virale et procédé pour l'obtention d'antiqènes d'hépatite virale | |
| US3415926A (en) | Equine encephalomyelitis vaccine | |
| DE2132911C2 (de) | Verfahren zum Herstellen eines stark abgeschwächte Rötelviren enthaltenden Impfstoffs | |
| RU2154496C2 (ru) | Вакцина против чумы, инфекционного гепатита и парвовирусного энтерита плотоядных | |
| DE2517550C3 (de) | Verfahren zum Herstellen eines Lebend-Impfstoffs zum Immunisieren von fleischfressenden Tieren gegen Staupe | |
| AT234902B (de) | Verfahren zur Herstellung einer Vaccine gegen Staupe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Designated state(s): AT CH DE FR LI |
|
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| AK | Designated contracting states |
Designated state(s): AT CH DE FR LI |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19851018 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: STECK, FRANZ, PROF. DR. |